Therma Bright Inc. announced that it has received IRB approval and subsequently submitted to Health Canada seeking approval to conduct a clinical performance study of its AcuVidTM Covid-19 Rapid Saliva-based Antigen Test. Therma's clinical research organization prepared and filed the necessary documentation for the IRB and Health Canada submissions. They are now focused on readying the trial site and personnel to begin the study once the Health Canada go ahead is received.